Major Pharma Sees Fading Short Interest
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway it actually can make with these reforms.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The December 31 short interest data have been compared with the previous figures, and short interest in all of these selected pharmaceutical stocks decreased.
Short interest in Pfizer Inc. (NYSE: PFE) decreased to 49.74 million shares from the previous 59.61 million. The stock was trading at $42.27 Friday morning, within a 52-week range of $33.20 to $46.47.
The number of Merck & Co. Inc. (NYSE: MRK) shares short fell to 47.24 million from 65.16 million in the previous period. Its shares were trading at $74.41, in a 52-week range of $52.83 to $80.19.
Bristol-Myers Squibb Co. (NYSE: BMY) short interest dropped to 12.69 million shares from the previous reading of 12.83 million. Shares traded at $47.24, in a 52-week trading range of $44.30 to $70.05.
The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 29.76 million from the previous 30.86 million. The stock was trading at $87.78, and its 52-week range is $77.50 to $125.86.
Eli Lilly and Co.’s (NYSE: LLY) short interest decreased slightly to 9.30 million shares from the previous 9.32 million. The stock was trading at $115.79. The 52-week range is $73.69 to $119.84.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest decreased to 36.76 million from the previous level of 44.52 million. Shares were trading at $18.24, in a 52-week range of $14.59 to $25.96.